Market Overview

Valeant Takes First Steps To De-Leverage Its Balance Sheet, Challenges Remain

Valeant Takes First Steps To De-Leverage Its Balance Sheet, Challenges Remain
Related VRX
56 Biggest Movers From Yesterday
Valeant Up 17% After Q3 Report
Tracking John Paulson's Paulson & Company Portfolio - Q3 2017 Update (Seeking Alpha)

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has taken its first significant steps toward de-levering its balance sheet, announcing the divestiture of Dendreon and several dermatology brands for combined cash consideration of ~2.1 billion,” Canaccord Genuity’s Neil Marouka said in a note.

Marouka maintains a Hold rating on the company, while raising the price target from $17 to $19.

De-Leveraging The Balance Sheet

The analyst believes these moves by Valeant Pharma are positive, although they highlight potential challenges within the process for the company, going forward.

“The ability to achieve higher valuations probably will require giving up higher-growth products; also, potential buyers may not be able to achieve the same synergies identified by Valeant when the assets were acquired,” Marouka mentioned.

Following the divestitures, the analyst estimated that the company would have total debt worth $28.3 billion remaining.

Discount Warranted

Although the announced assets sales are the biggest to date, Marouka noted that the valuations achieve were only slightly accretive to Valeant Pharma’s leverage ratio.

“Given Valeant’s elevated leverage, lower growth, and higher risk profile, we believe that a discount to the specialty pharma peer group is warranted,” the analyst went on to say.

In the meantime, positive data from Valeant Pharma’s second Phase III trials of IDP-118 indicate that there still are avenues of growth within the company’s pipeline.

Latest Ratings for VRX

Nov 2017Deutsche BankMaintainsHold
Nov 2017BMO CapitalMaintainsMarket Perform
Jul 2017Deutsche BankMaintainsHold

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Health Care Price Target Reiteration Asset Sales Analyst Ratings Best of Benzinga


Related Articles (VRX)

View Comments and Join the Discussion!

Partner Center